Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Effective Reduction of Anti-PEG Antibody Recognition via PEG Copolymers with Ethyl Glycidyl Ether and Isopropyl Glycidyl Ether.

Created on 14 Sep 2026

Authors

Verena Müller, Julian Schmidt, Rebecca Matthes, Philip Dreier, Sandra Schüttner, Matthias Bros, Holger Frey

Published in

Biomacromolecules. Volume 27. Issue 9. Pages 6165-6174. Sep 14, 2026.

Abstract

Anti-PEG antibodies (APAs) lead to accelerated blood clearance of PEGylated drugs and nanocarriers. Randomized PEG (rPEG) reduces APA recognition by randomly incorporating glycidyl methyl ether in PEG. Extending this concept, statistical copolymerization of ethylene oxide with ethyl glycidyl ether (EGE) or isopropyl glycidyl ether (iPGE) was investigated. Copolymers of EO with 13-28 mol % EGE or 6-20 mol % iPGE showed low dispersity (Đ ≤ 1.09). Via online-NMR monitoring, reactivity ratios in DMSO were rEO = 1.39 and rEGE = 0.72 for P(EO-co-EGE) and rEO = 1.35 and riPGE = 0.74 for P(EO-co-iPGE). All copolymers were soluble in PBS buffer at physiological temperatures and noncytotoxic, except for 20% iPGE content, shown by cell viability and immunostimulatory effects on murine splenocytes. All copolymers exhibit significantly reduced APA recognition (ELISA) with stronger effects for the sterically demanding iPGE. The findings highlight mP(EO-co-EGE) and mP(EO-co-iPGE) as promising PEG alternatives for nanomedicine and bioconjugation.

PMID:
42734265
Bibliographic data and abstract were imported from PubMed on 14 Sep 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 5
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement